In this video, health-care analyst David Williamson takes a closer look at two of the recent European Medicines Agency opinions -- one positive and one negative, even though both drugs have U.S. approval. Watch and find out what it means for Medivation investors and its competitors Johnson & Johnson and Dendreon now that metastatic prostate cancer drug Xtandi received a big thumbs-up from the agency. On the other side of the coin, Pfizer's first-in-class JAK-3 inhibitor for rheumatoid arthritis was knocked on both safety and efficacy, getting hit with a negative opinion. Pfizer's loss may be AbbVie's gain, as its injected best-selling RA drug, Humira, won't have to face an oral competitor.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.